Life Saving Drugs Program – Eliglustat (Cerdelga®) outcome statement
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
The Life Saving Drugs Program Expert Panel considered this application from Sanofi-Aventis Australia Pty Ltd on 15 November 2019. They deferred their decision until the Government-agreed outcomes from the Gaucher disease LSDP medicines review are known.